Crossmark

Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report

Published Online: 2020-03-14

Published Print: 2020-12

Authors

Simmons, Andrew D.

Nguyen, Minh

Pintus, Elias http://orcid.org/0000-0001-5123-1835
Funding

Funding for this research was provided by:

Clovis Oncology Inc (N/a)
License Information

Text and Data Mining valid from 2020-03-14

Version of Record valid from 2020-03-14
More Information

Article History

Received: 24 June 2019

Accepted: 18 February 2020

First Online: 14 March 2020

Ethics approval and consent to participate

: Not applicable.

: Patient written informed consent has been obtained. A copy of the consent form is available for review by the Editor of this journal.

: ADS and MN are employees of Clovis Oncology. EP reports a consulting or advisory role for Clovis Oncology; honoraria from Clovis Oncology, Astellas, Bristol-Myers Squibb, and Janssen; and travel support from Clovis Oncology, Astellas, Ipsen, and Janssen.

Document is current